1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
3 citations
,
April 2017 in “Clinical Drug Investigation” The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
25 citations
,
January 2006 in “Pharmacoepidemiology and drug safety” SSRIs can cause hair loss, especially sertraline, with higher risk in women.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
2 citations
,
October 2016 in “European Neuropsychopharmacology”
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
January 2025 in “International Journal of Pharmacology” Both steroids, especially cyproterone acetate, harm quail's vital organs.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
1 citations
,
July 1990 in “European Journal of Pharmacology” 64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
23 citations
,
October 2015 in “Andrology” New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.
Cyproterone acetate is an effective treatment for women with acne, hair loss, and excessive hair growth.
1 citations
,
January 2010 in “SRX Pharmacology” Bupropion SR may help treat trichotillomania.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
10 citations
,
April 1964 in “Journal of the American Geriatrics Society” Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
October 2025 in “Saúde (Santa Maria)” Spironolactone is an effective and safe treatment for acne in adult women.
6 citations
,
October 2016 in “Contraception” The medication cyproterone acetate/ethinylestradiol is usually prescribed correctly for acne after other treatments don't work.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.